AI assistant
Sending…
Cartesian Therapeutics, Inc. — Director's Dealing 2023
Nov 15, 2023
33483_dirs_2023-11-15_75773da4-e490-4543-91ed-2c7d75642bae.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13
Reporting Person: Jewell Christopher M (Chief Scientific Officer)
More from Cartesian Therapeutics, Inc.
Regulatory Filings
2026
May 26
Regulatory Filings
2026
Apr 30
Interim / Quarterly Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Proxy Solicitation & Information Statement
2026
Apr 28
Regulatory Filings
2026
Mar 30
Major Shareholding Notification
2026
Feb 5
Regulatory Filings
2026
Jan 9
Director's Dealing
2026
Jan 8
Director's Dealing
2026
Jan 8